window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : May 1, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

cell and gene therapy

  • Cell & Gene Therapy,Clinical studies,Clinical Trials,Pharmaceuticals and therapeutics,Research & Development

    EG 427 reports strong initial results for DNA therapy in neurogenic bladder trial

    EG 427 has released encouraging first clinical data from its [...]

    October 2, 2025
  • CDMOs & Manufacturing,Cell & Gene Therapy,Partnerships & Funding,Pharmaceuticals and therapeutics,Technology and platforms

    eXmoor Pharma and Siam Bioscience partner to expand cell and gene therapy services in Southeast Asia

    eXmoor Pharma and Siam Bioscience have announced a strategic partnership [...]

    September 23, 2025
  • CDMOs & Manufacturing,Cell & Gene Therapy,Movers & Shakers,Pharmaceuticals and therapeutics

    Chrysalis appoints Adam Bartley as chief operating officer

    Chrysalis, a provider of GMP cleanroom hosting and support services [...]

    September 23, 2025
  • Cell & Gene Therapy,Clinical Development,Partnerships & Funding

    Vitalant and UPMC expand partnership to advance cell and gene therapy initiatives

    Vitalant, a national blood and biotherapies provider, is expanding its [...]

    September 8, 2025
  • Cell & Gene Therapy,Clinical Development,Clinical Trials,European biotech,Partnerships & Funding,Patient Centricity

    Anocca raises SEK 440M to advance TCR-T cell therapies into clinical development

    Swedish clinical-stage biotech Anocca AB has secured approximately SEK 440 [...]

    August 19, 2025
  • Biologics & Biosimilars,Cell & Gene Therapy,Oncology

    Broken String renews NIST gene editing safety push with INDUCE-seq technology

    Broken String Biosciences has reaffirmed its commitment to supporting the [...]

    August 5, 2025
  • Cell & Gene Therapy,Clinical Development,Clinical Trials,Oncology

    Novotech report explores how in-vivo CAR-T could transform cell therapy access and costs

    A new whitepaper from Novotech has outlined how in-vivo CAR-T [...]

    July 18, 2025
  • CDMOs & Manufacturing,Cell & Gene Therapy,Oncology,Partnerships & Funding

    eXmoor and Signadori Bio partner to advance monocyte-based cell therapy for solid tumours

    New alliance focuses on translation, process development and GMP-readiness for [...]

    July 1, 2025
  • Artificial Intelligence,CDMOs & Manufacturing,Cell & Gene Therapy,Partnerships & Funding

    Unlocking collaboration: How data sharing and digital innovation are shaping the future of cell and gene therapy manufacturing

    The case for smarter collaboration in CGT manufacturing  As the [...]

    July 1, 2025
  • Cell & Gene Therapy,Regulatory Affairs

    UK experts urge Government to appoint Minister for cell and gene therapies

    Commission sets out 25 policy recommendations to unlock access and [...]

    June 23, 2025
Previous123Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Neomorph raises $100 million to advance NEO-811 Phase 1/2 cancer trial and molecular glue degrader pipeline
    Categories: Biotech, Clinical Trials, Drug discovery, Funding, Oncology, Partnerships & Funding, Pharmaceuticals and therapeutics, Research & Development, Technology and platforms
  • NICE expands Lokelma access for hyperkalaemia after draft recommendation
    Categories: Cardiovascular diseases, Chronic diseases, Market Access & Commercialization, Pharmaceuticals and therapeutics, Regulatory Affairs
  • Oncodesign expands ARRONAX deal to secure astatine-211 supply for radiotherapy research
    Categories: CDMOs & Manufacturing, Drug Development, European biotech, Logistics and distribution, Oncology, Partnerships & Funding, Supply Chain & Logistics
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top